Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

55.26 -1.36 (-2.40%)
Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,702,903
Open 56.46
Bid (Size) 55.20 (200)
Ask (Size) 55.42 (100)
Prev. Close 56.62
Today's Range 55.10 - 56.56
52wk Range 42.52 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 4.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗
Via Chartmill
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property

Performance

YTD
+3.4%
+3.4%
1 Month
+3.2%
+3.2%
3 Month
+26.7%
+26.7%
6 Month
+16.7%
+16.7%
1 Year
-2.0%
-2.0%

More News

Read More
Thursday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
3 Value Stocks That Fall Short
Via StockStory
News headline image
3 S&P 500 Stocks Walking a Fine Line
Via StockStory
Topics Stocks
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
Via MarketMinute
Topics Intellectual Property
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
1 Top ETF I Plan to Load Up on in 2026 ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
Via MarketMinute
Topics Intellectual Property
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
Via StockStory
Topics Stocks
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
2 Dividend Stocks to Scoop Up Without Hesitation Right Now ↗
Via The Motley Fool
Topics Bankruptcy Initial Public Offering
News headline image
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Economy Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 55.26
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 01/16/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 122.79B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 123B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.